Lonza Group AG is a Switzerland-based global provider of contract development and manufacturing services to the pharmaceutical, biotechnology and specialty ingredients markets. The company offers end-to-end solutions spanning drug substance and drug product development, clinical and commercial manufacturing, and regulatory support. Lonza’s service offerings include microbial fermentation, mammalian cell culture, cell and gene therapy, drug product fill–finish, and analytical testing, enabling clients to accelerate R&D timelines and scale production for both small-molecule and biologic therapies.
Lonza’s specialty ingredients business develops and manufactures a wide range of products for the personal care, food and nutrition, household and industrial markets. Its portfolio includes preservatives, active ingredients, delivery systems and bioengineered enzymes, designed to enhance product performance, stability and sustainability. Leveraging advanced formulation expertise and regulatory know-how, Lonza supports customers in addressing evolving consumer preferences, environmental regulations and product innovation challenges.
Founded in 1897 in the Swiss town of Rheinmünster after the discovery of a magnesium smelter at the confluence of the Rhine River, Lonza originally produced hydroelectric power and magnesium metal. Over the decades, the company expanded into chemicals, agrochemicals and biotechnology, later divesting noncore businesses to focus on life sciences. A landmark transaction was the 2017 acquisition of Capsugel, which broadened Lonza’s drug product capabilities with hard-capsule and delivery technologies and reinforced its position in the global contract development and manufacturing organization (CDMO) sector.
Today, Lonza operates across Europe, North America and the Asia-Pacific region, with state-of-the-art manufacturing facilities in Switzerland, the United States, Singapore, China and beyond. Under the leadership of CEO Dr. David Veasey, who assumed the role in 2019, the company continues to invest in capacity expansion, digitalization and sustainable production practices. Lonza’s global footprint and integrated service model strive to meet the increasing demand for innovative therapies and specialty ingredients while maintaining high standards of quality and regulatory compliance.
AI Generated. May Contain Errors.
